All In Biotech

Free tool

FAERS Monitor: Voyxact

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761434 or its brand name (Voyxact, Sibeprenlimab-Szsi). Reports on generic versions are filed under their own applications.

Reports

689

Serious

114

17% of reports

Hospitalization

56

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injection site pain100
  • injection site swelling75
  • fatigue68
  • injection site erythema51
  • injection site pruritus47
  • nasopharyngitis43
  • cough32
  • injection site bruising32
  • nausea32
  • dizziness29
  • headache24
  • diarrhoea23
  • illness23
  • underdose23
  • upper respiratory tract infection22

Reports by year received

View as table
YearReports
20242
20256
2026681

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,470 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
injection site swellingSignal7529.924.22,072
injection site pruritusSignal4721.416.3897
upper respiratory tract infectionSignal2214.59.6265
injection site erythemaSignal5112.69.6534
injection site bruisingSignal3212.28.7321
injection site painSignal10010.08.3808
underdoseSignal239.66.4170
nasopharyngitisSignal437.15.3222
illnessSignal236.84.6109
coughSignal323.52.555
fatigueSignal682.72.172
dizziness291.81.29
nausea321.20.91
headache241.20.80
diarrhoea231.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.